Lantheus (NASDAQ:LNTH) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS
Lantheus (NASDAQ:LNTH) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS
Lantheus (NASDAQ:LNTH – Get Rating) released its quarterly earnings results on Thursday. The medical equipment provider reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.25, Briefing.com reports. Lantheus had a return on equity of 28.88% and a net margin of 4.88%. The company had revenue of $223.80 million during the quarter, compared to analysts' expectations of $204.51 million. During the same quarter in the prior year, the business posted $0.11 earnings per share. The company's revenue for the quarter was up 121.4% compared to the same quarter last year. Lantheus updated its FY 2022 guidance to $3.50-$3.60 EPS and its Q3 2022 guidance to $0.80-$0.85 EPS.
兰修斯(纳斯达克:LNTH-GET评级)周四发布了季度收益业绩。据Briefing.com报道,这家医疗设备提供商公布本季度每股收益(EPS)为0.89美元,比普遍预期的0.64美元高出0.25美元。兰修斯的股本回报率为28.88%,净利润率为4.88%。该公司本季度营收为2.238亿美元,高于分析师预期的2.0451亿美元。在去年同一季度,该业务公布的每股收益为0.11美元。该公司本季度的收入与去年同期相比增长了121.4%。Lantheus将其2022财年每股收益指引更新为3.50-3.60美元,将2022年第三季度每股收益指引更新为0.80-0.85美元。
Lantheus Price Performance
兰修斯性价比
Shares of Lantheus stock traded up $7.33 during trading on Friday, hitting $78.57. The stock had a trading volume of 1,703,905 shares, compared to its average volume of 1,357,643. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.64. The firm has a market cap of $5.39 billion, a P/E ratio of 182.72 and a beta of 0.79. The business has a fifty day moving average of $67.85 and a two-hundred day moving average of $55.77. Lantheus has a fifty-two week low of $22.20 and a fifty-two week high of $81.43.
在周五的交易中,Lantheus的股价上涨了7.33美元,达到78.57美元。该股成交量为1,703,905股,而其平均成交量为1,357,643股。该公司的债务权益比为0.27,流动比率为1.85,速动比率为1.64。该公司的市值为53.9亿美元,市盈率为182.72,贝塔系数为0.79.该业务的50日移动均线切入位在67.85美元,200日移动均线切入位在55.77美元。兰修斯的52周低点为22.20美元,52周高点为81.43美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several research firms have recently issued reports on LNTH. Truist Financial increased their price target on Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. B. Riley started coverage on Lantheus in a research note on Monday, May 9th. They issued a "buy" rating and a $91.00 price target for the company. Finally, SVB Leerink upped their price objective on Lantheus from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Friday.
几家研究公司最近发布了关于LNTH的报告。Truist Financial在5月2日星期一的一份研究报告中将其对Lantheus的目标价从77.00美元上调至94.00美元。B.莱利在5月9日星期一的一份研究报告中开始了对兰修斯的报道。他们对该公司的评级为买入,目标价为91.00美元。最后,SVB Leerink在上周五的一份报告中将兰修斯的目标价从100.00美元上调至110.00美元,并给予该公司“跑赢大盘”的评级。
Insider Activity
内幕活动
Institutional Investors Weigh In On Lantheus
机构投资者看好兰修斯
Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Lantheus by 32.9% during the first quarter. Vanguard Group Inc. now owns 5,742,083 shares of the medical equipment provider's stock valued at $317,595,000 after buying an additional 1,422,269 shares during the period. Bank of New York Mellon Corp raised its position in Lantheus by 2.7% during the first quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider's stock valued at $34,791,000 after buying an additional 16,422 shares during the period. Invesco Ltd. raised its position in Lantheus by 1.3% during the first quarter. Invesco Ltd. now owns 522,633 shares of the medical equipment provider's stock valued at $28,908,000 after buying an additional 6,706 shares during the period. Charles Schwab Investment Management Inc. raised its position in Lantheus by 9.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 522,322 shares of the medical equipment provider's stock valued at $28,890,000 after buying an additional 44,180 shares during the period. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Lantheus during the first quarter valued at $17,813,000. 97.14% of the stock is owned by hedge funds and other institutional investors.
几家对冲基金最近调整了对该股的持有量。先锋集团(Vanguard Group Inc.)第一季度将其在兰修斯的头寸提高了32.9%。先锋集团现在持有这家医疗设备供应商5,742,083股股票,价值317,595,000美元,在此期间又购买了1,422,269股。纽约梅隆银行(Bank Of New York Mellon Corp)第一季度将其在Lantheus的头寸提高了2.7%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有这家医疗设备提供商629,033股股票,价值34,791,000美元,在此期间又购买了16,422股。景顺股份有限公司在第一季度将其在Lantheus的持仓提高了1.3%。景顺公司目前持有这家医疗设备供应商的522,633股股票,价值28,908,000美元,在此期间又购买了6,706股。嘉信理财(Charles Schwab Investment Management Inc.)第一季度将其在兰修斯的持仓提高了9.2%。嘉信理财投资管理公司(Charles Schwab Investment Management Inc.)目前持有这家医疗设备提供商522,322股股票,价值28,890,000美元,在此期间又购买了44,180股。最后,Fuller&Thaler Asset Management Inc.在第一季度收购了兰修斯的一个新头寸,价值17,813,000美元。97.14%的股票由对冲基金和其他机构投资者持有。
About Lantheus
关于兰修斯
(Get Rating)
(获取评级)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
兰修斯控股公司开发、制造和商业化诊断和治疗产品,帮助世界各地的临床医生诊断和治疗心脏病、癌症和其他疾病。它提供了用于心脏超声检查的微气泡超声增强剂DEFINITY;用于核医学的氚发生器TechneLite;用于评估肺功能的Xenon-133;用于确定大脑内因中风而血流受阻或减少的区域的Neurolite;可注射的Tc-99m标记显像剂心脏;用于检测心血管疾病的铊-201;以及用于检测各种感染和癌症肿瘤的镓-67。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免费获取StockNews.com关于兰修斯的研究报告(LNTH)
- MarketBeat:回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升,是时候收购了吗?
- Beyond Meat不是没有希望,而且它很便宜
- 苹果为何可能在年底创下历史新高
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
接受兰修斯日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Lantheus和相关公司的最新新闻和分析师评级的每日简要摘要。